Summit Clinical Trials for Ivonescimab (SMT112)
Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in the U.S. & EU.*
Brings two validated mechanisms in oncology1,2,3 into ONE novel tetravalent molecule.
For Information on the Ivonescimab MOA
For additional information on the HARMONi or the HARMONi-3 clinical trials, please visit clinicaltrials.gov or contact email@example.com